Loading...
SYRS logo

Syros Pharmaceuticals, Inc.OTCPK:SYRS Aktierapport

Marknadsvärde US$2.7k
Aktiekurs
n/a
1Y-99.7%
7D0%
1D0%
Portföljens värde
​
Utsikt

Syros Pharmaceuticals, Inc.

OTCPK:SYRS Aktierapport

Börsvärde: US$2.7k

Syros Pharmaceuticals (SYRS) Aktievy

Syros Pharmaceuticals, Inc. är ett biofarmaceutiskt företag som fokuserar på utveckling av behandlingar för hematologiska maligniteter. Mer information

SYRS fundamental analys
Snöflinga Score
Värdering0/6
Framtida tillväxt0/6
Tidigare resultat0/6
Finansiell hälsa0/6
Utdelningar0/6

Riskanalys

De senaste finansiella rapporterna är mer än ett år gamla

Har inte ett meningsfullt börsvärde ( $3K )

Mycket volatil aktiekurs under de senaste 3 månaderna jämfört med US marknaden


SYRS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Syros Pharmaceuticals, Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Syros Pharmaceuticals
Historiska aktiekurser
Aktuell aktiekursUS$0.0001
52 veckors högstaUS$0.04
52 veckors lägstaUS$0.000001
Beta0
1 månads förändring-50.00%
3 månaders förändring-71.43%
1 års förändring-99.66%
3 års förändring-99.90%
5 års förändring-99.90%
Förändring sedan börsintroduktionen-99.90%

Senaste nyheter och uppdateringar

Recent updates

Seeking Alpha • Jul 02

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has encouraging data from a phase 2 trial and is currently conducting a phase 3 trial, but lack of asset diversification and high risk should be considered. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Summary Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with the merger, the largest shareholders put in an additional $130m into the company at over 30% premium to current prices. This strong vote of confidence from insiders makes SYRS very interesting, especially when shares are below insiders' entry price. SYRS share price has just declined by 17%, presenting an attractive entry point. SYRS now trades materially below net cash while being fully funded to bring development programs to fruition. The merger between Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) was announced in the beginning of July and closed last Friday. This opportunity attracted our interest purely from the merger arb perspective but it actually had two angles to it (with the second one being the key point of this article): Pure merger arbitrage play - pretty much till the closing the spread on the merger stood at 20-40% (chart below) and we could not see any real risks in this transaction despite our best efforts to dig something out. Although such a wide spread on a merger with limited risks might seem too-good-to-true, we actually spot similar opportunities quite often in the less analyzed microcap space and cover them on our premium service Special Situation Investing. The merger arb aspect of the transaction has now fully played out, but there is another angle to the story. Another angle of TYME / SYRS transaction is that SYRS is a very well-positioned pharma company with an attractive development portfolio and this merger simply was an opportunity to acquire SYRS at 20-30% discount to the prevailing market prices by buying it through TYME. Now that the merger closed, one can no longer acquire TYME stock with hopes it will convert to SYRS, but luckily enough SYRS is now itself trading materially below the levels of the merger announcement, presenting an equally attractive opportunity as was acquiring it through TYME. Why the wide spread on the merger? Note: You can easily skip to the next section as this one only looks at a strange market inefficiency in these types of situations. TYME/SYRS Merger Spread Despite our attempts to find an explanation for this wide 20-40% spread, we could not find anything. So in the end we concluded that this is one of those micro-cap merger arbitrage situations where the market is simply not paying attention and our research actually gives us an edge. We love these types of opportunities and covered these regularly on Special Situation Investing. The spread on SYRS / TYME merger seemed completely overblown given the short expected closing timeline, persistently cheap SYRS hedging fees and very low risk of merger termination. The merger was basically an equity raise for SYRS. The buyer openly stated that it was interested solely in TYME's net cash position ($60m) to enhance its liquidity and indicated that TYME's existing drug development program will be put on hold. Shareholder approvals seemed guaranteed as around 35% of SYRS and 30% of TYME shares had already been in support. The PIPE financing for an additional $130m from the largest shareholders at a premium to the market prices added further confidence that every single party of the transaction wants this to close successfully. As expected, shareholder approvals were received on the 15th of September and the merger closed a day later. As further proof of market inefficiency in these types of situations, the spread still persisted even after the shareholder approval. After the vote SYRS issued an announcement stating that the merger will close the next day but the spread persisted and even increased slightly to 10%. Only by the end of the day the spread was finally eliminated. What's next for SYRS? Note: post-merger closing, SYRS has effected a 10-to-1 reverse stock split. Further calculations refer to SYRS's share price and count after the split. Aside from raising cash through the merger with TYME, SYRS also simultaneously did a huge $130m PIPE (vs $50m market cap at the time) at $0.94/share ($9.40/share adjusted for the recent split). The participants were mostly major shareholders of the company - large and reputable PE firms including Bain Capital, Invus Public Equities, Ally Bridge MedAlpha, and others. SYRS co-founder and founding investor Flagship Pioneering also participated. The fact that these firms, who have significantly more knowledge and information about the SYRS pipeline have put that much money at over 30% premium to current prices adds significant confidence in the value of the company's current pipeline. It's no secret that biopharma investing is largely a gamble. However, one thing for sure is that such reputable firms do not like throwing good money after the bad, and especially not in this size. Both transactions have now provided SYRS with enough cash runway through 2025. Post-merger, SYRS has 27.9m of outstanding shares and total cash of ~$240m (after deducting transaction expenses). Net cash is at ~$200m or ~$7.16 per SYRS share. SYRS is down 17% on the first day after the merger close and now sits close to an all-time-low at $6.08/share. The stock is currently trading 15% below net cash and over 35% discount to where the largest shareholders have just made a material investment. SYRS Net Cash Before the merger, SYRS used to trade at up to 8-10% discount to net cash. However, right now the company is in much better shape - a very strong cash position and no financing/dilution risk until 2026 - should be enough to advance its main treatment Tamibarotene into commercialization. If Tamibarotene shows good phase 3 results, the upside from current levels will be very material. These points, as well as the recent vote of confidence from major shareholders, suggest that 15% discount to net cash is overly punitive.
Seeking Alpha • Sep 13

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Syros Pharmaceuticals (NASDAQ:SYRS) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer, SYRS said in a statement. The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition. SYRS stock +4.5% to $0.80 after hours.
Seeking Alpha • Aug 08

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Aktieägarnas avkastning

SYRSUS BiotechsUS Marknad
7D0%5.1%-2.7%
1Y-99.7%36.7%18.6%

Avkastning vs industri: SYRS presterade sämre än US Biotechs branschen som gav 36.7 % under det senaste året.

Avkastning vs Marknaden: SYRS presterade sämre än US marknaden som gav 18.6 % under det senaste året.

Prisvolatilitet

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement10,254.8%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stabil aktiekurs: SYRS s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: SYRS s veckovolatilitet har ökat från 5194% till 10255% under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
2011n/an/awww.syros.com

Syros Pharmaceuticals, Inc. är ett biofarmaceutiskt företag som fokuserar på utveckling av behandlingar för hematologiska maligniteter. Bolagets ledande produktkandidater är Tamibarotene, en selektiv retinoinsyrareceptor alfa-agonist, som befinner sig i klinisk fas III-studie för genomiskt definierad undergrupp av patienter med myelodysplastiskt syndrom och klinisk fas II-studie för patienter med akut myeloisk leukemi; SY-2101, en ny oral form av arseniktrioxid för behandling av patienter med akut promyelocytisk leukemi; och SY-5609, en cyklinberoende kinase 7-hämmare, som befinner sig i en klinisk fas I-studie på patienter med utvalda avancerade solida tumörer. Bolaget var tidigare känt som LS22, Inc. och bytte namn till Syros Pharmaceuticals, Inc. i augusti 2012.

Syros Pharmaceuticals, Inc. Sammanfattning av grunderna

Hur förhåller sig Syros Pharmaceuticals:s resultat och omsättning till dess börsvärde?
SYRS grundläggande statistik
BörsvärdeUS$2.68k
Vinst(TTM)-US$97.81m
Intäkter(TTM)US$386.00k
0.0x
P/S-förhållande
0.0x
P/E-förhållande

Är SYRS övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
SYRS resultaträkning (TTM)
IntäkterUS$386.00k
Kostnad för intäkterUS$88.64m
Bruttovinst-US$88.25m
Övriga kostnaderUS$9.56m
Intäkter-US$97.81m

Senast redovisade vinst

Sep 30, 2024

Nästa vinstdatum

n/a

Vinst per aktie (EPS)0
Bruttomarginal0.00%
Nettovinstmarginal0.00%
Skuld/egenkapitalförhållande0.0%

Hur har SYRS utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/06/25 14:41
Aktiekurs vid dagens slut2026/06/25 00:00
Intäkter2024/09/30
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Syros Pharmaceuticals, Inc. bevakas av 4 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Mark BreidenbachOppenheimer & Co. Inc.
Zegbeh JallahRoth Capital Partners
Philip NadeauTD Cowen